{"id":48473,"date":"2025-11-17T19:51:58","date_gmt":"2025-11-17T11:51:58","guid":{"rendered":"https:\/\/flcube.com\/?p=48473"},"modified":"2025-11-17T19:51:59","modified_gmt":"2025-11-17T11:51:59","slug":"msd-acquires-cidara-therapeutics-in-9-2%e2%80%91billion-deal-to-expand-antiviral-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48473","title":{"rendered":"MSD Acquires Cidara Therapeutics in $9.2\u2011Billion Deal to Expand Antiviral Portfolio"},"content":{"rendered":"\n<p><strong>Merck Sharp &amp;\u202fDohme Inc.<\/strong> (MSD, <a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:NYSE\">NYSE: MRK<\/a>) disclosed a definitive acquisition agreement with <strong>Cidara Therapeutics,\u202fInc.<\/strong> (CDTX). Through its subsidiary <strong>Merck Research and Development LLC<\/strong>, MSD will buy Cidara for <strong>$221.50 per share in cash<\/strong>, valuing the transaction at <strong>\u2248\u202f$9.2\u202fbillion<\/strong> (about 12\u202f% premium to March\u202f2025 market price).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-deal-mechanics\">Deal Mechanics<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Transaction Structure<\/strong><\/td><td>Cash\u2011only offer at <strong>$221.50\/share<\/strong><\/td><\/tr><tr><td><strong>Total Enterprise Value<\/strong><\/td><td><strong>\u2248\u202f$9.2\u202fbillion<\/strong> (USD)<\/td><\/tr><tr><td><strong>Funding Source<\/strong><\/td><td>Merck\u2019s wholly\u2011owned subsidiary<\/td><\/tr><tr><td><strong>Closing Timeline<\/strong><\/td><td>Subject to customary regulatory and shareholder approvals (expected Q2\u202f2026)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The purchase price represents a premium of roughly 12\u202f% over Cidara\u2019s last trading price, underscoring Merck\u2019s strategic intent to broaden its infectious\u2011disease pipeline beyond its existing biologic and vaccine platforms.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-cidara-s-antigen-free-antiviral-platform\">Cidara\u2019s Antigen\u2011Free Antiviral Platform<\/h3>\n\n\n\n<p>Cidara has developed a novel class of <strong>drug\u2011Fc conjugates (DFCs)<\/strong> that fuse multiple copies of a potent neuraminidase inhibitor to a proprietary human Fc fragment. Unlike vaccines or monoclonal antibodies, DFCs are <em>low\u2011molecular\u2011weight biologics<\/em> engineered for long\u2011acting pharmacokinetics.<\/p>\n\n\n\n<p><strong>Lead candidate: CD388 (CD388\u2011DFC)<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong> \u2013 Multi\u2011shaped neuraminidase inhibitor covalently attached to a human Fc domain; activity is independent of host immune activation.<\/li>\n\n\n\n<li><strong>Intended Indication<\/strong> \u2013 Seasonal, <em>season\u2011long<\/em> protection against influenza in high\u2011risk populations (e.g., seniors, immunocompromised).<\/li>\n\n\n\n<li><strong>Benefits<\/strong> \u2013 \u201cOne\u2011dose\u201d dosing that eliminates the need for repeated vaccination and offers consistent efficacy irrespective of patient antibody status.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-rationale-for-merck\">Strategic Rationale for Merck<\/h3>\n\n\n\n<p>Merck has long been the <strong>global leader in vaccine development<\/strong> (influenza, COVID\u201119) but its pipeline has been dominated by immunologic agents. The acquisition of Cidara\u2019s <strong>DFC technology<\/strong> aligns with several corporate priorities:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Diversifying Antiviral Offerings<\/strong> \u2013 Adds a non\u2011vaccine, small\u2011molecule platform that can complement Merck\u2019s current influenza portfolio.<\/li>\n\n\n\n<li><strong>Crossover Potential<\/strong> \u2013 DFCs may be adapted to other viral targets (e.g., RSV, SARS\u2011CoV\u20112) using the same conjugation chemistry.<\/li>\n\n\n\n<li><strong>Commercial Synergy<\/strong> \u2013 Merck\u2019s scale will accelerate global distribution, leveraging its existing influenza immunization network while introducing a new product category.<\/li>\n<\/ol>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This briefing contains forward\u2011looking statements about Merck\u2019s acquisition, Cidara\u2019s technology, and future commercial prospects. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck Sharp &amp;\u202fDohme Inc. (MSD, NYSE: MRK) disclosed a definitive acquisition agreement with Cidara Therapeutics,\u202fInc&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":48475,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4463,2675,176,903],"class_list":["post-48473","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cidara-therapeutics","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>MSD Acquires Cidara Therapeutics in $9.2\u2011Billion Deal to Expand Antiviral Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck Sharp &amp;\u202fDohme Inc. (MSD, NYSE: MRK) disclosed a definitive acquisition agreement with Cidara Therapeutics,\u202fInc. (CDTX). Through its subsidiary Merck Research and Development LLC, MSD will buy Cidara for $221.50 per share in cash, valuing the transaction at \u2248\u202f$9.2\u202fbillion (about 12\u202f% premium to March\u202f2025 market price).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48473\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MSD Acquires Cidara Therapeutics in $9.2\u2011Billion Deal to Expand Antiviral Portfolio\" \/>\n<meta property=\"og:description\" content=\"Merck Sharp &amp;\u202fDohme Inc. (MSD, NYSE: MRK) disclosed a definitive acquisition agreement with Cidara Therapeutics,\u202fInc. (CDTX). Through its subsidiary Merck Research and Development LLC, MSD will buy Cidara for $221.50 per share in cash, valuing the transaction at \u2248\u202f$9.2\u202fbillion (about 12\u202f% premium to March\u202f2025 market price).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48473\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-17T11:51:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-17T11:51:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1704-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48473#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48473\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MSD Acquires Cidara Therapeutics in $9.2\u2011Billion Deal to Expand Antiviral Portfolio\",\"datePublished\":\"2025-11-17T11:51:58+00:00\",\"dateModified\":\"2025-11-17T11:51:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48473\"},\"wordCount\":356,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48473#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1704-1.webp\",\"keywords\":[\"Cidara Therapeutics\",\"Merck Sharp &amp; Dohme\",\"MSD\",\"NYSE: MRK\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48473#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48473\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48473\",\"name\":\"MSD Acquires Cidara Therapeutics in $9.2\u2011Billion Deal to Expand Antiviral Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48473#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48473#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1704-1.webp\",\"datePublished\":\"2025-11-17T11:51:58+00:00\",\"dateModified\":\"2025-11-17T11:51:59+00:00\",\"description\":\"Merck Sharp &\u202fDohme Inc. (MSD, NYSE: MRK) disclosed a definitive acquisition agreement with Cidara Therapeutics,\u202fInc. (CDTX). Through its subsidiary Merck Research and Development LLC, MSD will buy Cidara for $221.50 per share in cash, valuing the transaction at \u2248\u202f$9.2\u202fbillion (about 12\u202f% premium to March\u202f2025 market price).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48473#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48473\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48473#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1704-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1704-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"MSD Acquires Cidara Therapeutics in $9.2\u2011Billion Deal to Expand Antiviral Portfolio\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48473#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MSD Acquires Cidara Therapeutics in $9.2\u2011Billion Deal to Expand Antiviral Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MSD Acquires Cidara Therapeutics in $9.2\u2011Billion Deal to Expand Antiviral Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"Merck Sharp &\u202fDohme Inc. (MSD, NYSE: MRK) disclosed a definitive acquisition agreement with Cidara Therapeutics,\u202fInc. (CDTX). Through its subsidiary Merck Research and Development LLC, MSD will buy Cidara for $221.50 per share in cash, valuing the transaction at \u2248\u202f$9.2\u202fbillion (about 12\u202f% premium to March\u202f2025 market price).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48473","og_locale":"en_US","og_type":"article","og_title":"MSD Acquires Cidara Therapeutics in $9.2\u2011Billion Deal to Expand Antiviral Portfolio","og_description":"Merck Sharp &\u202fDohme Inc. (MSD, NYSE: MRK) disclosed a definitive acquisition agreement with Cidara Therapeutics,\u202fInc. (CDTX). Through its subsidiary Merck Research and Development LLC, MSD will buy Cidara for $221.50 per share in cash, valuing the transaction at \u2248\u202f$9.2\u202fbillion (about 12\u202f% premium to March\u202f2025 market price).","og_url":"https:\/\/flcube.com\/?p=48473","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-17T11:51:58+00:00","article_modified_time":"2025-11-17T11:51:59+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1704-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48473#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48473"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MSD Acquires Cidara Therapeutics in $9.2\u2011Billion Deal to Expand Antiviral Portfolio","datePublished":"2025-11-17T11:51:58+00:00","dateModified":"2025-11-17T11:51:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48473"},"wordCount":356,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48473#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1704-1.webp","keywords":["Cidara Therapeutics","Merck Sharp &amp; Dohme","MSD","NYSE: MRK"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48473#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48473","url":"https:\/\/flcube.com\/?p=48473","name":"MSD Acquires Cidara Therapeutics in $9.2\u2011Billion Deal to Expand Antiviral Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48473#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48473#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1704-1.webp","datePublished":"2025-11-17T11:51:58+00:00","dateModified":"2025-11-17T11:51:59+00:00","description":"Merck Sharp &\u202fDohme Inc. (MSD, NYSE: MRK) disclosed a definitive acquisition agreement with Cidara Therapeutics,\u202fInc. (CDTX). Through its subsidiary Merck Research and Development LLC, MSD will buy Cidara for $221.50 per share in cash, valuing the transaction at \u2248\u202f$9.2\u202fbillion (about 12\u202f% premium to March\u202f2025 market price).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48473#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48473"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48473#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1704-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1704-1.webp","width":1080,"height":608,"caption":"MSD Acquires Cidara Therapeutics in $9.2\u2011Billion Deal to Expand Antiviral Portfolio"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48473#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MSD Acquires Cidara Therapeutics in $9.2\u2011Billion Deal to Expand Antiviral Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1704-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48473","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48473"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48473\/revisions"}],"predecessor-version":[{"id":48476,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48473\/revisions\/48476"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48475"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48473"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48473"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48473"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}